|
| Drug type | Disease condition | Phase | Study type | Trial number |
|
| Small molecule drugs |
| Farglitazar (GI262570), PPARγ agonist | Liver fibrosis with chronic HCV infection | 2 | Safety/efficacy study | NCT00244751 |
| Pioglitazone, PPARγ agonist | NASH | 2 | Safety/efficacy study | NCT01068444 |
| Pioglitazone, PPARγ agonist + vitamin E | NAFLD with diabetes mellitus type 2 (T2DM) | 4 | Efficacy study | NCT01002547 |
| Pioglitazone, PPARγ agonist + vitamin E | Nondiabetic patients with NASH | 3 | Efficacy study | NCT00063622
(PIVENS) |
| Pioglitazone, PPARγ agonist | Hepatic steatosis in HIV/HCV infections | 4 | Efficacy study | NCT00742326 |
| Obeticholic acid, FXR agonist | NASH fibrosis | 3 | Efficacy study | NCT02548351 |
| Obeticholic acid, FXR agonist | Primary biliary cirrhosis | 3 | Safety/efficacy study | NCT02308111; NCT01473524 |
| Obeticholic acid, FXR agonist | NASH | 2 | Efficacy study | NCT01265498 |
| Obeticholic acid, FXR agonist | Primary sclerosing cholangitis | 2 | Safety/efficacy study | NCT02177136 |
| Obeticholic acid, FXR agonist + ursodeoxycholic acid (URSO) | Primary biliary cirrhosis | 2 | Safety/efficacy study | NCT00550862 |
| Losartan, angiotensin II type 1 receptor antagonist | Liver fibrosis (F2-F3) with chronic HCV infection | 4 | Efficacy study | NCT00298714 |
| Losartan, angiotensin II type 1 receptor antagonist | NASH | 4 | Efficacy study | NCT01051219 |
| Irbesartan, angiotensin II type 1 receptor antagonist | Liver fibrosis with chronic HCV infection | 3 | Efficacy study | NCT00265642 |
| Moexipril, angiotensin I converting enzyme | Primary biliary cirrhosis | 2 | Safety/efficacy study | NCT00588302 |
| Candesartan, angiotensin II type 1 receptor antagonist | Alcoholic liver fibrosis | 1 + 2 | Safety/efficacy study | NCT00990639 |
| Candesartan, angiotensin II type 1 receptor antagonist | Liver fibrosis with chronic HCV infection | 2 | Safety/efficacy study | NCT00930995 |
| Glycyrrhizin, antioxidant | Chronic hepatitis C and F2/F3 liver fibrosis | 3 | Efficacy study | NCT00686881 |
| Warfarin, anticoagulant | Liver fibrosis | 2 | Safety/efficacy study | NCT00180674 |
| Galectin-3 inhibitor (GR-MD-02) | NASH with advanced fibrosis | 2 | Safety/efficacy study | NCT02421094 |
| Galectin-3 inhibitor (GR-MD-02) | Portal hypertension in NASH with cirrhosis | 2 | Safety/efficacy study | NCT02462967 |
| Pentoxifylline, TNFα suppressing phosphodiesterase inhibitor | Primary biliary cirrhosis | 2 | Safety/efficacy study | NCT01249092 |
| Pentoxifylline, TNFα suppressing phosphodiesterase inhibitor + vitamin E | Liver fibrosis with chronic HCV infection | 3 | Efficacy study | NCT00119119 |
| Pentoxifylline, TNFα suppressing phosphodiesterase inhibitor | NASH | 2/3 | Safety/efficacy study | NCT00267670 |
| Pentoxifylline, TNFα suppressing phosphodiesterase inhibitor | NASH | 2 | Efficacy study | NCT00590161 |
| S-adenosyl methionine (SAMe) versus pentoxifylline | NASH | 2 | Efficacy study | NCT02231333 |
| Cenicriviroc, CCR2 and CCR5 antagonist | NASH | 2 | Safety/efficacy study | NCT02217475 |
| Fuzheng Huayu, herbal medicine | Liver fibrosis with chronic HCV infection | 2 | Efficacy study | NCT00854087 |
| Sorafenib, tyrosine kinase inhibitor | Liver cirrhosis with portal hypertension | 2 | Efficacy study | NCT01714609 |
| Erlotinib, EGFR TK inhibitor | Liver cirrhosis with HCC resection | 2 | Safety/efficacy study | NCT02273362 |
| Everolimus, mammalian target of rapamycin inhibitor | Liver fibrosis in posttransplant and recurrent HCV patients | 2/3 | Safety/efficacy study | NCT00582738, NCT01888432 |
|
| Monoclonal antibodies |
| Simtuzumab, humanized monoclonal antibody against lysyl oxidase-like-2 | NASH with advanced liver fibrosis | 2 | Safety/efficacy study | NCT01672866 |
| Simtuzumab, humanized monoclonal antibody against lysyl oxidase-like-2 | Liver fibrosis with hepatitis C, HIV, HIV/HCV coinfection | 2 | Safety/efficacy study | NCT01707472 |
| Simtuzumab, humanized monoclonal antibody against lysyl oxidase-like-2 | Liver fibrosis with primary sclerosing cholangitis (PSC) | 2 | Safety/efficacy study | NCT01672853 |
| Simtuzumab, humanized monoclonal antibody against lysyl oxidase-like-2 + Selonsertib (GS-4997)-apoptosis signal-regulating kinase 1 (ASK1) inhibitor | NASH and fibrosis stages F2-F3 | 2 | Safety/efficacy study | NCT02466516 |
| FG-3019, Human monoclonal antibody against connective tissue growth factor | Liver fibrosis with chronic hepatitis B infection | 2 | Safety/efficacy study | NCT01217632 |
|
| Targeted conjugate |
| Targeted liposome delivering siRNA against HSP47 (ND-L02-s0201) | Healthy subjects | 1 | Safety study | NCT01858935 |
| Targeted liposome delivering siRNA against HSP47 (ND-L02-s0201) | Moderate to extensive hepatic fibrosis (F3-4) | 1/2 | Safety/efficacy study | NCT02227459 |
|
